http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Sat, 18 Aug 2018 02:07:37 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Proposed directorate change ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180806070007_13744122/ Mon, 06 Aug 2018 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180806070007_13744122/ <![CDATA[RNS press release - Director's dealing ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180731100434_13737622/ Tue, 31 Jul 2018 10:04:34 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180731100434_13737622/ <![CDATA[Media files - Optibiotix is a very clever business model says chairman ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9906/optibiotix-is-a-very-clever-business-model-says-chairman-9906.html Thu, 19 Jul 2018 15:16:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9906/optibiotix-is-a-very-clever-business-model-says-chairman-9906.html <![CDATA[Media files - Investors 'beginning to realise the potential' in OptiBiotix Health - CEO ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9873/investors-beginning-to-realise-the-potential-in-optibiotix-health-ceo-9873.html Tue, 17 Jul 2018 13:12:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9873/investors-beginning-to-realise-the-potential-in-optibiotix-health-ceo-9873.html <![CDATA[RNS press release - Grant of Options ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180717070011_13719899/ Tue, 17 Jul 2018 07:00:11 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180717070011_13719899/ <![CDATA[RNS press release - Director's dealing ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180712070007_13714763/ Thu, 12 Jul 2018 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180712070007_13714763/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180706120003_13708975/ Fri, 06 Jul 2018 12:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180706120003_13708975/ <![CDATA[RNS press release - Result of AGM ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704140754_13705788/ Wed, 04 Jul 2018 14:07:54 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704140754_13705788/ <![CDATA[News - OptiBiotix appoints director of research & development ]]> http://www.proactiveinvestors.co.uk/companies/news/200102/optibiotix-appoints-director-of-research-development-200102.html OptiBiotix Health PLC (LON:OPTI) said it has appointed Dr Sofia Kolyda as director of research & development with immediate effect.

The AIM-listed life sciences group, which develops compounds to tackle obesity, high cholesterol, and diabetes, said Kolyda’s expertise had been important in the development of its technology through laboratory studies, human studies and manufacturing scale up, which had allowed it to create a pipeline of products.

READ: OptiBiotix signs agreement with global corporate for SweetBiotix product

The firm added that Kolyda’s scientific leadership had been key to the company winning best scientific publication at the Probiota industry event in 2017 and 2018.

OptiBiotix also said that under Kolyda’s tenure it had secured agreements with several global corporates, including Tata for microbiome modulation and two agreements for its SweetBiotix range of sweeteners, the first with one of the world's largest suppliers of nutritional products and the second with one of the world's largest providers of dairy products.

Given the high levels of interest in SweetBiotix, Kolyda would take responsibility for leading development programmes with current and future corporate partners.

]]>
Wed, 04 Jul 2018 08:05:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/200102/optibiotix-appoints-director-of-research-development-200102.html
<![CDATA[RNS press release - Directorate Change ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704070004_13704571/ Wed, 04 Jul 2018 07:00:04 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180704070004_13704571/ <![CDATA[News - OptiBiotix signs agreement with global corporate for SweetBiotix product ]]> http://www.proactiveinvestors.co.uk/companies/news/199549/optibiotix-signs-agreement-with-global-corporate-for-sweetbiotix-product-199549.html OptiBiotix Health PLC (LON:OPTI) has announced that it has entered into an agreement with a global corporate for its SweetBiotix low-calorie sweet fibres.

The FTSE 100-listed firm said the agreement sets out the terms and grants exclusivity, for a period of six months, to negotiate a license agreement for the scale-up, manufacture and distribution of its SweetBiotix product.

READ: OptiBiotix inks licence agreement for LPLDL compound in Italy

The life sciences company said it will receive monthly payments during this exclusivity period amounting to a six-figure sum

OptiBiotix did not reveal the name of the company, but said it is a global supplier of nutritional and agricultural products to companies around the world with an annual turnover exceeding US$100bn.

Stephen O'Hara, CEO of OptiBiotix, commented: “This is the second agreement with global partners for products created from our SweetBiotix development programmes. This is part of a strategy of working with global partners to support scale-up, manufacture and commercialisation of a range of SweetBiotix products in well-known consumer brands.”

He added: “With international concerns over the balance of sugars and fibres in consumer diets rising, OptiBiotix's is at the forefront of product development in this area of growing industry and commercial interest."

In a note to clients, analysts at finnCap said: “Whilst there is no certainty that the negotiations will lead to a full licence, this agreement could be very substantial given the scale of the corporate with which it has had initial discussions.”

In morning trading, OptiBiotix shares jumped 3.8% to 67.00p.

 -- Adds broker comment, share price --

]]>
Tue, 26 Jun 2018 07:28:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/199549/optibiotix-signs-agreement-with-global-corporate-for-sweetbiotix-product-199549.html
<![CDATA[RNS press release - Agreement with global corporate for SweetBiotix® ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180626070001_13692994/ Tue, 26 Jun 2018 07:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180626070001_13692994/ <![CDATA[Media files - OptiBiotix Health Plc enters into exclusive licensing deal for LPLDL in Italy ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9640/optibiotix-health-plc-enters-into-exclusive-licensing-deal-for-lpldl-in-italy-9640.html Thu, 21 Jun 2018 08:01:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9640/optibiotix-health-plc-enters-into-exclusive-licensing-deal-for-lpldl-in-italy-9640.html <![CDATA[News - OptiBiotix inks licence agreement for LPLDL compound in Italy ]]> http://www.proactiveinvestors.co.uk/companies/news/199285/optibiotix-inks-licence-agreement-for-lpldl-compound-in-italy-199285.html OptiBiotix Health plc (LON:OPTI) has signed a licence agreement to commercialise food supplements containing its LPLDL strain in the Italian market.

The AIM-listed life sciences company, which develops compounds to tackle obesity, high cholesterol, diabetes and skin care, said the 10-year agreement would grant ALFASIGMA, a multinational pharmaceutical company, a licence to promote food supplements containing the LPLDL strain for cardiovascular health, throughout Italy. 

READ: First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in U

The group added that the agreement would include an upfront payment and royalties with five-figure guaranteed minimum payments.

Italy is the largest probiotic supplement market in Europe and the second largest market in the world with a value of over US$500mln and a 25% per annum growth forecast to 2021.

Per Rehne, commercial director of OptiBiotix, said: “This agreement is another deal from a very strong pipeline with industry partners of increasing size and revenue potential targeted at the largest and fastest growing markets around the world."

The agreement follows the launch of OptiBiotix’s LPLDL strain in the US market after the company struck a deal with US supplement maker, Seed Health, in May.

]]>
Thu, 21 Jun 2018 07:35:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/199285/optibiotix-inks-licence-agreement-for-lpldl-compound-in-italy-199285.html
<![CDATA[RNS press release - Exclusive license agreement for LPLDL® ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180621070003_13687809/ Thu, 21 Jun 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180621070003_13687809/ <![CDATA[News - OptiBiotix strikes SlimBiome manufacturing and supply deal with Morley Foods ]]> http://www.proactiveinvestors.co.uk/companies/news/198997/optibiotix-strikes-slimbiome-manufacturing-and-supply-deal-with-morley-foods-198997.html OptiBiotix Health plc (LON:OPTI) has signed an exclusive deal with John Morley Foods to manufacture and supply SlimBiome in muesli packs within the UK.

Morleys supplies ingredients to major retailers and several consumer food brands and has spent the last six months developing a range of muesli products which contain SlimBiome – a patented combination of natural ingredients which provide hunger-free weight loss.

READ: First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in US

The muesli will be sold as own-label products to major retailers and as extensions to existing well-known brands.

Alongside the manufacturing and supply part of the deal, Morleys’ job is also to promote the SlimBiome muesli packs. In return for its efforts, Morleys will take 50% cut of any profits generated.

“We chose Morleys due to their reputation as one of the UK's leading suppliers of specialist ingredients and the energy and passion they have shown in developing a wide range of muesli products containing SlimBiome over the last six months,” said chief executive Stephen O’Hara.

“We believe working with Morleys, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and global brands who are looking to develop healthy products to meet growing consumer demand.”

]]>
Mon, 18 Jun 2018 07:36:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/198997/optibiotix-strikes-slimbiome-manufacturing-and-supply-deal-with-morley-foods-198997.html
<![CDATA[RNS press release - Manufacturing agreement with Morley Foods ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180618070004_13682605/ Mon, 18 Jun 2018 07:00:04 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180618070004_13682605/ <![CDATA[RNS press release - Exercise of Options and Issue of Equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180614070003_13679006/ Thu, 14 Jun 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180614070003_13679006/ <![CDATA[RNS press release - Notice of AGM ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180611070004_13673674/ Mon, 11 Jun 2018 07:00:04 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180611070004_13673674/ <![CDATA[News - First supplement containing OptiBiotix’s breakthrough cholesterol-lowering strain launched in US ]]> http://www.proactiveinvestors.co.uk/companies/news/198419/first-supplement-containing-optibiotixs-breakthrough-cholesterol-lowering-strain-launched-in-us-198419.html A dietary supplement containing OptiBiotix Health plc’s (LON:OPTI) cholesterol and blood pressure-reducing LPLDL strain has launched in the US.

Seed Health struck a deal with AIM-quoted Opti to produce, market and commercialise products containing the LPLDL strain in May.

READ: OptiBiotix inks US deal for breakthrough cholesterol strain

The US supplements maker has now launched its Daily Symbiotic capsules which can be bought directly through its website.

It is a significant achievement for OptiBiotix, marking its entry into one of the largest and fastest-growing probiotic markets in the world and one which is expected to be worth more than US$3bn by 2021.

Boss wants more product launches

“We are excited to see the launch of products containing our cholesterol reducing LPLDL strain in the USA, the world's largest and fastest growing probiotic market,” said Opti’s chief executive Stephen O’Hara.

“The launch with Seed substantiates the science behind LPLDL and helps build the LPLDL brand in the consumer healthcare market around the world.”

He added: “We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL as the active component in a wide range of products in the USA and around the world.”

]]>
Thu, 07 Jun 2018 07:31:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/198419/first-supplement-containing-optibiotixs-breakthrough-cholesterol-lowering-strain-launched-in-us-198419.html
<![CDATA[RNS press release - US launch of LPLDL® with Seed Health ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180607070004_13670040/ Thu, 07 Jun 2018 07:00:04 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180607070004_13670040/ <![CDATA[News - OptiBiotix signs evaluation agreement with a global dairy company for SweetBiotix product ]]> http://www.proactiveinvestors.co.uk/companies/news/197982/optibiotix-signs-evaluation-agreement-with-a-global-dairy-company-for-sweetbiotix-product-197982.html OptiBiotix Health plc (LON:OPTI) has announced it has entered into an evaluation agreement with a global dairy company for its SweetBiotix calorie-free sweet fibres.

The AIM-listed company said the agreement grants a non-exclusive licence for an evaluation period to explore the potential for using the SweetBiotix technology to reduce the sugar content in a range of its dairy food products.

READ: OptiBiotix Health raises £1.5mln in oversubscribed placing to capitalise on opportunities

OptiBiotix revealed that the undisclosed company is a global brand and one of the world’s largest providers of dairy products with an annual turnover exceeding US$10bn.

The company, which is developing compounds to tackle obesity, high cholesterol and diabetes, has previously announced that the five successful human taste studies on the SweetBiotix product development had created interest from several companies.

OPtiBiotix said this agreement reflects interest from one of these companies in exploring the use of SweetBiotix in its branded dairy products.

Stephen O’Hara, CEO of the company, said: “This is part of a strategy of working with global partners who have the capability and expertise to manufacture speciality ingredients like SweetBiotix and well-known consumer brands who have the specialist application expertise to incorporate this technology in to their own branded breaded, dairy, cereal and beverage consumer products.”

He added: “This approach provides a low-risk way to fully exploit the wide range of opportunities offered by our SweetBiotix technology.”

]]>
Thu, 31 May 2018 07:32:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197982/optibiotix-signs-evaluation-agreement-with-a-global-dairy-company-for-sweetbiotix-product-197982.html
<![CDATA[RNS press release - SweetBiotix® agreement with global dairy company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180531070002_13660641/ Thu, 31 May 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180531070002_13660641/ <![CDATA[Media files - OptiBiotix Health raises £1.5mln to capitalise on new opportunities ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9404/optibiotix-health-raises-15mln-to-capitalise-on-new-opportunities-9404.html Wed, 30 May 2018 15:51:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9404/optibiotix-health-raises-15mln-to-capitalise-on-new-opportunities-9404.html <![CDATA[News - OptiBiotix Health - investors like what they see ]]> http://www.proactiveinvestors.co.uk/companies/news/197929/optibiotix-health-investors-like-what-they-see-197929.html The fact its latest share issue was keenly priced and yet still over-subscribed, tells you all you need to know about OptiBiotix Health PLC (LON:OPTI).

Investors like the business, which is using its expertise in the human microbiome to develop food additives and pharmaceutical products that tackle ailments and diseases of our era – obesity, high cholesterol and diabetes.

Proceeds from the £1.5mln placing, conducted at a modest discount to last night’s close, will be used to super-charge progress.

It follows hard on the heels of a series of deals that will help propel the business forward commercially. And this progress is at the heart of why OptiBiotix is tapping investors for cash.

READ: Today's news in full

One of the opportunities open to the business is to develop cholesterol buster LPLDL as a pharmaceutical as well as food additive. 

Potential partners are willing to fund regulatory submissions and clinical studies, but OptiBiotix will be required to invest in developing process controls and quality procedures.

The cash injection will also be used to fully exploit opportunities for sweetener SweetBiotix and to promote SlimBiome, its weight loss product.

"The company has received a high level of partner interest in its technology and products across new application areas and territories that have the potential for significant value uplift," said chief executive Stephen O'Hara.

"It has become clear that new opportunities, particularly the development of LPLDL into a pharmaceutical product, the high level of corporate interest in SweetBiotix across multiple applications, and the potential for listing a range of health and wellbeing products with major retailers are not achievable in the short term within current resources. 

No delay to opportunities 

"Rather than delay these opportunities until OptiBiotix has sufficient revenues to cover costs, the Board has decided to take additional funds to capitalise on these growth opportunities and build shareholder value. 

"Whilst the subscription was oversubscribed the company has limited the funds received to ensure a focus on value creation and has added new institutional investors to the share register."

As mentioned above, OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

After spinning off its SkinBio business as a separately-listed entity last year, the group is now focused on three development areas referred to above – cholesterol, diabetes and weight loss.

Transition made

In the last year, it has inked a deal with an offshoot of Premier Foods that makes Birds Custard, Indian giant Tata and Seed Health in the US.

finnCap, the OptiBiotix’s corporate broker, has been impressed with progress made by CEO O’Hara and his expanded commercial team.

Analyst Mark Brewer in a note to clients pointed out the group has transitioned from being technology-focused to one that inked 16 commercial agreements last financial year and this.  

“This significantly de-risks the business,” he added Brewer.

“The focus for the current year will be to begin to convert these agreements into revenues; the timing and quantum of which remains difficult to forecast.”  

]]>
Wed, 30 May 2018 13:04:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197929/optibiotix-health-investors-like-what-they-see-197929.html
<![CDATA[News - OptiBiotix Health raises £1.5mln in oversubscribed placing to capitalise on opportunities ]]> http://www.proactiveinvestors.co.uk/companies/news/197887/optibiotix-health-raises-15mln-in-oversubscribed-placing-to-capitalise-on-opportunities-197887.html OptiBiotix Health plc (LON:OPTI) said it has raised £1.5mln in an oversubscribed share placing – cash that will be used to capitalise on commercial opportunities for three key products.

The company, which is developing advances that use the human microbiome to tackle obesity, high cholesterol and diabetes, is issuing the new stock at 62p, a modest discount to Tuesday's closing price.

One of the opportunities open to the business is to develop cholesterol buster LPLDL, as a pharmaceutical as well as food additive. 

Potential partners

Potential partners are willing to fund regulatory submissions and clinical studies, but OptiBiotix it will be required to invest in developing process controls and quality procedures.

The company said the cash injection will also be used to "fully exploit" opportunities for sweetener SweetBiotix and to promote SlimBiome, its weight loss product.

"The company has received a high level of partner interest in its technology and products across new application areas and territories that have the potential for significant value uplift," said chief executive Stephen O'Hara.

"It has become clear that new opportunities, particularly the development of LPLDL into a pharmaceutical product, the high level of corporate interest in SweetBiotix across multiple applications, and the potential for listing a range of health and wellbeing products with major retailers are not achievable in the short term within current resources. 

Opportunities

"Rather than delay these opportunities until OptiBiotix has sufficient revenues to cover costs, the Board has decided to take additional funds to capitalise on these growth opportunities and build shareholder value. 

"Whilst the subscription was oversubscribed the company has limited the funds received to ensure a focus on value creation and has added new institutional investors to the share register."

 

]]>
Wed, 30 May 2018 07:29:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197887/optibiotix-health-raises-15mln-in-oversubscribed-placing-to-capitalise-on-opportunities-197887.html
<![CDATA[RNS press release - Placing and Issue of Equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180530070005_13658861/ Wed, 30 May 2018 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180530070005_13658861/ <![CDATA[News - OptiBiotix has high hopes for "significant revenues" from its burgeoning deal pipeline ]]> http://www.proactiveinvestors.co.uk/companies/news/197513/optibiotix-has-high-hopes-for-significant-revenues-from-its-burgeoning-deal-pipeline-197513.html A revaluation of its stake in SkinBiotherapeutics following the skincare subsidiary's flotation in April catapulted OptiBiotix Health plc (LON:OPTI) into the black last year.

The income statement included an adjustment of £4.1mln for the change in value of the investment in SkinBioTherapeutics PLC (LON:SBTX) following the listing – the value of the stake has since increased further – resulting in a profit before tax in the year to November 30, 2018, of £1.69mln, compared to a loss the previous year of £1.52mln.

READ: OptiBiotix Health inks US deal for cholesterol breakthrough​

OptiBiotix noted that the adjustment in the value of the stake in SkinBiotherapeutics was paper-based, not cash-based, and as such is not taxable.

“We have been pleased with the progress of SkinBioTherapeutics PLC, which is making strong commercial progress and preparing for human studies, which if successful, should provide a substantive uplift in valuation,” said Stephen O'Hara, the chief executive officer of OptiBiotix.

The life sciences business, focused on tackling obesity, high cholesterol and diabetes, saw revenue ease to £191,073 from £288,119 but stressed that as the company makes the transition from the research stage to the commercial phase, it is developing a deal pipeline that it believes will develop into significant revenues over time.

Administrative expenses rose to £2.24mln from £1.77mln the previous year, resulting in an operating loss of £2.13mln, versus a loss the previous year of £1.52mln.

Theresa May to unveil a new anti-obesity strategy within weeks https://t.co/nQVRWICQQ6

— Jack Shakespeare (@JShakespearePA) May 20, 2018

"OptiBiotix has made significant progress in the last 12 months, which has seen a growing number of awards for our science and products and an increased deal flow. We anticipate both the rate and value of deal flow increasing as we develop new applications, take existing products into new territories, and leverage our technology platforms to develop new product opportunities,” O'Hara said.

“We are particularly excited by the interest from partners in developing our products into biopharmaceuticals and see this as an area of significant future development and potential value uplift,” he added.

]]>
Wed, 23 May 2018 07:36:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197513/optibiotix-has-high-hopes-for-significant-revenues-from-its-burgeoning-deal-pipeline-197513.html
<![CDATA[RNS press release - Final Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180523070006_13651273/ Wed, 23 May 2018 07:00:06 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180523070006_13651273/ <![CDATA[News - OptiBiotix Health inks US deal for cholesterol breakthrough ]]> http://www.proactiveinvestors.co.uk/companies/news/197423/optibiotix-health-inks-us-deal-for-cholesterol-breakthrough-197423.html OptiBiotix Health PLC (LON:OPTI) confirmed it has inked a deal with Seed Health, which will produce, promote, market and commercialise in the US products containing the former's cholesterol-lowering additive, LP-LDL.

Financial details of the non-exclusive agreement weren't disclosed. But, investors were told Seed has developed a product concept which combines multiple strains of different probiotics that have been selected because of strong clinical trial data. 

WATCH: OptiBiotix scoops award for Weight Management Ingredient of the Year

OptiBiotix's LP-LDL strain has published human data demonstrating significant statistical and clinical reductions in cholesterol and blood pressure.

Shared vision 

"We chose Seed due to our shared vision of commercialising products with strong scientific and clinical data, their innovative product concept, and their ability to access the large US consumer goods market," said chief executive Stephen O'Hara.  

"We are pleased that our strong science, successful human studies and international awards at major scientific conferences has attracted international interest in our products leading to continued regular deal flow as we build multiple revenue streams from partners across the world."

Optibiotix has developed a number of compounds that interact with the human microbiome to tackle obesity, high cholesterol, diabetes and skin complaints.

Complex interaction 

The microbiome is a complex interaction of bacteria that exists in the gut and on the skin and it's known fine tweaks to it can affect and improve health.

LP-LDL is one of a number of developments by CEO O'Hara and his team that tap into huge potential markets. 

America is one of the largest and fastest growing probiotic markets in the world, with supplement sales currently around US$2.1bn annually and the market expected to grow to US$3.3bn by 2021.

Partner Seed was co-founded and is led by Raja Dhir and Ara Katz to pioneer the application of microbiome science. 

In collaboration with leading scientists and a global network of partners and experts in biofermentation, stabilisation and testing, Seed reckons it has developed a new standard for a pipeline of effective, scientifically-validated probiotics that target the human microbiome. 

The shares, up 23% in the last month, advanced 2.4% early on to 74p, valuing the business at just shy of £60mln.

---- adds share price ----

 

]]>
Tue, 22 May 2018 07:48:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197423/optibiotix-health-inks-us-deal-for-cholesterol-breakthrough-197423.html
<![CDATA[RNS press release - LP-LDL agreement for USA ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180522070002_13649544/ Tue, 22 May 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180522070002_13649544/ <![CDATA[Media files - OptiBiotix scoops award for Weight Management Ingredient of the Year ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9335/optibiotix-scoops-award-for-weight-management-ingredient-of-the-year-9335.html Mon, 21 May 2018 08:42:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9335/optibiotix-scoops-award-for-weight-management-ingredient-of-the-year-9335.html <![CDATA[News - OptiBiotix SlimBiome wins award for Weight Management Ingredient of the Year ]]> http://www.proactiveinvestors.co.uk/companies/news/197254/optibiotix-slimbiome-wins-award-for-weight-management-ingredient-of-the-year-197254.html OptiBiotix Health plc (LON:OPTI) has announced that its weight management ingredient SlimBiome has won the award for Weight Management Ingredient of the Year at the Vitafoods European tradeshow in Geneva.

The AIM-listed firm said the award is given to the product identified by a panel of scientific, regulatory and industry experts demonstrating leading edge research and innovation in the weight management market.

READ: OptiBiotix to bring cholesterol reduction product to India with new agreement

OptiBiotix, which develops a range of compounds to tackle obesity, high cholesterol, diabetes and skin care, said the award for Weight Management Ingredient of the Year at Vitafoods is the second industry award for SlimBiome.

In November 2017 SlimBiome won the award for ‘Best Functional Ingredient for Health and Well Being’ at Food Matters.

Stephen O’Hara, CEO of OptiBiotix, said: “Having a product with a known mechanism of action, clinical and consumer studies showing its safety and effectiveness, and the support of leading international key opinion leaders, helps give confidence to consumers in their product choice.”

He added: “Hunger free dieting is now a consumer option and we hope that the increasing number of food applications containing SlimBiome will help bring the benefits of this exciting new technology to a wider international audience."

  

]]>
Fri, 18 May 2018 07:33:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197254/optibiotix-slimbiome-wins-award-for-weight-management-ingredient-of-the-year-197254.html
<![CDATA[RNS press release - SlimBiome® wins award at Vitafoods 2018 ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180518070005_13646132/ Fri, 18 May 2018 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180518070005_13646132/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516164039_13644111/ Wed, 16 May 2018 16:40:39 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516164039_13644111/ <![CDATA[News - OptiBiotix to bring cholesterol reduction product to India with new agreement ]]> http://www.proactiveinvestors.co.uk/companies/news/197069/optibiotix-to-bring-cholesterol-reduction-product-to-india-with-new-agreement-197069.html OptiBiotix Health PLC (LON:OPTI) has signed a five-year exclusive manufacturing and supply agreement for its cholesterol and blood pressure reducing strain in India.

The AIM-listed company, which develops a range of compounds to tackle obesity, high cholesterol, diabetes and skin care, said the agreement was with Akums Drugs and Pharmaceuticals Ltd, a leading contract manufacturer in India.

READ: OptiBiotix to present new products and research data at leading industry trade show next week

Under the terms of the agreement, Akums will manufacture and supply products containing OptiBiotix’s LPLDL strain throughout India to maximise financial return for both parties.

In return for exclusivity, the group said Akums would provide undisclosed and in-kind contributions and explore opportunities to utilise LPLDL with OptiBiotix therapeutics in India, including any required authority registrations.

Akums will also contribute to any required human studies for product marketing purposes or by the Food Safety Standards Authority of India (FSSAI) as part of product registration into food.

Optibiotix added that the agreement does not have any minimum sales orders and that it would update the market on sales in due course.

Akums is the largest contract manufacturing organisation in India, supplying more than 12% of all food and drug supplements consumed in the country, and has manufacturing partnerships with over 600 companies including Abbott (NYSE:ABT), Novartis, P&G (NYSE:PG), Sanofi and Sandoz, in the pharmaceutical and food supplement space.

Stephen O’Hara, OptiBiotix chief executive, said in a statement: "We are excited to announce this agreement with Akums which expands manufacturing and sales of LPLDL® into Asia. We chose Akums as they are the largest contract manufacturing company in India for both food supplements and pharmaceuticals and have extensive experience in manufacturing products for some of the biggest food and pharmaceutical companies in the world.

He added: "This agreement is a strategic step to add manufacturing to the supply chain in the Asian probiotic supplement and pharmaceutical market and extends the commercial reach of OptiBiotix's LPLDL® strain into Southern Asia. This allows OptiBiotix to offer multiple product solutions to consumer health and pharmaceutical companies within the region.

"This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, white label and own label branded consumer and pharmaceutical products, across multiple channels, with leading industry partners from around the world."

In a note to clients, analysts at City broker finnCap said the agreement was “further evidence of the foundations that OptiBiotix is building for its LP-LDL probiotic strain.”

They added: “This represents the ninth agreement for LP-LDL and continues to demonstrate the company’s ability to attract high calibre, global partners, eager to utilise the potential cardiovascular benefits inherent within LP-LDL.”

In late-morning trading, OptiBiotix shares were steady around 73.5p.

-- Adds broker comment and share price --

]]>
Wed, 16 May 2018 07:31:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/197069/optibiotix-to-bring-cholesterol-reduction-product-to-india-with-new-agreement-197069.html
<![CDATA[RNS press release - Exclusive manufacturing and supply agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516070003_13642559/ Wed, 16 May 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180516070003_13642559/ <![CDATA[News - OptiBiotix to present new products and research data at leading industry trade show next week ]]> http://www.proactiveinvestors.co.uk/companies/news/196520/optibiotix-to-present-new-products-and-research-data-at-leading-industry-trade-show-next-week-196520.html OptiBiotix Health plc (LON:OPTI) is to show off a range of new SlimBiome products and the latest research data on its LPLDL heart health products at a prestigious industry conference in Switzerland next week.

The life sciences group has been developing a range of new product concepts which feature its SlimBiome weight loss ingredient, including natural fruit gummies, muesli pots, Nutri-Bites and flavours for new bars; all of which it will showcase at Vitafoods European trade show in Geneva next week.

READ: OptiBiotix jumps on news of potential commercial partner SlimBiome and LPLDL nominated for awards

Opti will also present results from its human studies on SlimBiome which showed that people who took the ingredient felt fuller, had less cravings and were more likely or make positive changes to their food choices.

Alongside its manufacturing partner, Sacco, the AIM-listed company will also showcase its LPLDL cholesterol and blood pressure-reducing probiotic in a number of new product concepts, while Opti will also present fresh results of its human studies.

OptiBiotix is also up for a couple of awards at the conference: SlimBiome has been shortlisted for the 'Ingredient of the Year: Weight Management' award, while LPLDL has been shortlisted as 'Probiotic Product of the Year'.

New opportunities

“We are extremely pleased to be attending Vitafoods with a range of new products, new human studies on SlimBiome and a growing list of industry partners,” said chief executive Stephen O’Hara.

“We are confident that our participation at VitaFoods will help progress existing discussions with corporate partners and open up opportunities in new territories for the manufacture and distribution of our growing range of products.”

He added: “Finally, we are really excited by the results of the human study on SlimBiome.”

]]>
Tue, 08 May 2018 07:37:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/196520/optibiotix-to-present-new-products-and-research-data-at-leading-industry-trade-show-next-week-196520.html
<![CDATA[RNS press release - Launch of extended range of products at Vitafoods ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180508070008_13631744/ Tue, 08 May 2018 07:00:08 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180508070008_13631744/ <![CDATA[News - OptiBiotix shares jump amid media interest generated by potential US commercial partner ]]> http://www.proactiveinvestors.co.uk/companies/news/196125/optibiotix-shares-jump-amid-media-interest-generated-by-potential-us-commercial-partner-196125.html OptiBiotix Health plc (LON:OPTI) saw its shares jump on Tuesday after the life science firm noted media interest generated by a potential commercial partner, Seed Health.

In a statement, the AIM-listed firm - which is developing compounds to tackle obesity, high cholesterol, diabetes and skin care - pointed out that Seed has purchased its LP-LD product for use in a multi-strain product intended for launch in the US in May 2018.

READ: OptiBiotix signs agreement with Cambridge Commodities to distribute SlimBiome in the UK

The group noted that an article in Business Insider US refers to clinical studies published in the scientific journal PLOS One showing that one of the probiotics contained in Seed's multi-strain product reduced LDL or "bad" cholesterol and increased HDL or "good" cholesterol.

OptiBiotix reported the results of its human studies using LP-LD in April 2016, and subsequently published them in PLOS in December 2017 and at international conferences, which demonstrated statistical and clinical significant reductions in cholesterol and blood pressure.

The group said the Business Insider article provides a link to OptiBiotix's publication and discloses the use of LP-LDL in Seeds’ product.

OptiBiotix said it can confirm it is in discussions with Seed to agree commercial terms for the use of its LP-LDL strain in Seed's products in preparation for a May launch in the US.

The group added: “Whilst these negotiations are at an advanced stage, they are one of a number of discussions with US partners which may or may not progress to legal agreement. If or when commercial terms are concluded, a further announcement with be made.”

Seed have developed an innovative product concept which combines multiple strains of different probiotics which have been selected because of strong clinical trial data.

International commercial and media interest

Stephen O'Hara, OptiBiotix’s CEO, commented: "We are pleased that the strong science, successful human studies and international awards at major scientific conferences have attracted international commercial and media interest in LP-LDL.”

He added: “This has allowed OptiBiotix to sign manufacturing, formulation/application and distribution partnerships with fast-growing companies with leading market positions in multiple industry sectors across the world.

“We look forward to the opportunity of announcing deals with similar partners in the fast-growing US marker once these have been concluded."

In early trading, OptiBiotix shares were 8.7% higher at 75p.

]]>
Tue, 01 May 2018 08:45:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/196125/optibiotix-shares-jump-amid-media-interest-generated-by-potential-us-commercial-partner-196125.html
<![CDATA[RNS press release - LP-LDL? news media interest in USA ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180501070003_13624744/ Tue, 01 May 2018 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180501070003_13624744/ <![CDATA[RNS press release - Notice of Results ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180430070018_13622822/ Mon, 30 Apr 2018 07:00:18 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180430070018_13622822/ <![CDATA[Media files - OptiBiotix inks deal with Cambridge Commodities to distribute SlimBiome in UK ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/9142/optibiotix-inks-deal-with-cambridge-commodities-to-distribute-slimbiome-in-uk-9142.html Wed, 25 Apr 2018 12:47:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/9142/optibiotix-inks-deal-with-cambridge-commodities-to-distribute-slimbiome-in-uk-9142.html <![CDATA[News - OptiBiotix signs agreement with Cambridge Commodities to distribute SlimBiome in the UK ]]> http://www.proactiveinvestors.co.uk/companies/news/195626/optibiotix-signs-agreement-with-cambridge-commodities-to-distribute-slimbiome-in-the-uk-195626.html OptiBiotix Health PLC (LON:OPTI) has entered into a non-exclusive agreement for Cambridge Commodities Ltd (CCL) to distribute its SlimBiome weight management technology in the UK.

The AIM-listed firm said the SlimBiome product will be purchased from OptiBiotix and distributed as a specialised branded functional ingredient by CCL - a privately-owned firm which has 10 sales offices covering UK, Europe, USA and South Africa.

WATCH: OptiBiotix inks deal with Cambridge Commodities to distribute SlimBiome in UK

The company said in a statement that the agreement with CCL is complementary to the deal it signed with Knighton Food Ltd on 1 November 2017, as it extends SlimBiome’s commercial reach into new application areas where CCL has specific sector expertise, such as sports, health & wellbeing and ingredients sectors.

Stephen O’Hara, CEO of OptiBiotix, commented: “We believe working with CCL, and similar partners around the world, provides the best opportunity to expand the range of applications for SlimBiome to a wide range of industry sectors.”

He added: “This agreement is another step in our low-cost approach to growing revenues by building manufacturing, formulation/application and distribution partnership which provide revenues across the whole value chain in multiple industry sectors.”

]]>
Tue, 24 Apr 2018 07:32:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/195626/optibiotix-signs-agreement-with-cambridge-commodities-to-distribute-slimbiome-in-the-uk-195626.html
<![CDATA[RNS press release - SlimBiome non-exclusive UK distribution agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180424070002_13615392/ Tue, 24 Apr 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180424070002_13615392/ <![CDATA[News - OptiBiotix appoints new head of online sales and marketing to develop firm’s web presence ]]> http://www.proactiveinvestors.co.uk/companies/news/195337/optibiotix-appoints-new-head-of-online-sales-and-marketing-to-develop-firms-web-presence-195337.html OptiBiotix Health plc (LON:OPTI) has announced the appointment of Steven Riley as head of online sales and marketing from May 2, to develop the company’s web presence.

The AIM-listed firm said Riley - who has over eight years' sales and marketing experience within the food, nutrition and nutraceuticals industries - will lead the development of the OptiBiotix online presence as another revenue generating business in its own right.  

READ: OptiBiotix expands sales into Asia after inking five-year distribution deal with Pakistan pharma

The company said it will use the online platform as a display window to attract potential partners, as they did with GoFigure, which led to a deal with Tata Chemical for its SlimBiome product.

Optibiotix added: "The Company will extend its offering online with the CholBiome range that should enable it to attract further partners for LPLDL such as Trigen Pharma as announced on 18 April 2018."

Per Rehne, Optibiotix's commercial director said: "We want to develop this as display window to attract B2B partners and major retailers. This creates another channel for OptiBiotix that will generate revenues from OptiBiotix’s growing pipeline of products and we believe it has the potential to grow into a business in its own right.”

 

]]>
Thu, 19 Apr 2018 08:03:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/195337/optibiotix-appoints-new-head-of-online-sales-and-marketing-to-develop-firms-web-presence-195337.html
<![CDATA[RNS press release - Appointment of Head of Online Sales and Marketing ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180419070005_13610234/ Thu, 19 Apr 2018 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180419070005_13610234/ <![CDATA[News - OptiBiotix expands sales into Asia after inking five-year distribution deal with Pakistan pharma ]]> http://www.proactiveinvestors.co.uk/companies/news/195223/optibiotix-expands-sales-into-asia-after-inking-five-year-distribution-deal-with-pakistan-pharma-195223.html Life sciences group OptiBiotix Health plc (LON:OPTI) is taking its heart health products into Asia after signing an exclusive five-year distribution agreement with Trigen Pharma.

The deal will see Trigen – one of Pakistan’s leading healthcare groups – promote, distribute and commercialise Opti’s own-label CholBiome products in the South Asian country.

READ: OptiBiotix announces three new patent filings in sweetener market

In return for the exclusivity, Trigen has agreed to cover all costs for product registration with the Drug Regulatory Authority of Pakistan.

The agreement is the first covering the CholBiome range of products and expands Opti’s sales into Asia – a market with huge potential for the company.

In Pakistan alone, cardiovascular disease is responsible for about one-in-five deaths, and more than a third of over-45s suffer from hypertension (high blood pressure).

CholBiome contains OptiBiotix’s LPLDL strain and has been shown to reduce both cholesterol levels and blood pressure.

The AIM-quoted firm said products are difficult to estimate in new markets, but it expects them to be in the low-to-mid six-figures in the near term as Trigen builds market presence.

Strategic step to access Asian market

“We are pleased to announce this agreement with Trigen which expands sales of LPLDL into Pakistan, where high blood pressure and high cholesterol are significant causes of morbidity and mortality,” said chief executive Stephen O’Hara.

“We chose Trigen due to its leading position in Pakistan's pharmaceutical industry, specialism in cardiovascular health, and track record of growing product sales.

“This agreement is a strategic step to access the Asian probiotic market and extend the distribution of OptiBiotix's own label LPLDL formulations like CholBiome into international markets.”

]]>
Wed, 18 Apr 2018 07:41:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/195223/optibiotix-expands-sales-into-asia-after-inking-five-year-distribution-deal-with-pakistan-pharma-195223.html
<![CDATA[RNS press release - CholBiome exclusive distribution agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180418070002_13608389/ Wed, 18 Apr 2018 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20180418070002_13608389/ <![CDATA[News - OptiBiotix Health announces three new patent filings in the sweetener market ]]> http://www.proactiveinvestors.co.uk/companies/news/194307/optibiotix-health-announces-three-new-patent-filings-in-the-sweetener-market-194307.html OptiBiotix Health plc (LON:OPTI) has announced three new patent filings to protect the production methods and product application areas arising from its SweetBiotix product development programmes.

The AIM-listed firm said the first patent filing is a natural high-intensity sweetener with improved flavour profile and microbiome modulating functionality.

READ: OptiBiotix Health sweetener performs well in independent taste test

OptiBiotix also announced a patent filing for sweet natural healthy fibres, being developed as potential bulk sugar replacements which are not digested in the human gut, and hence calorie free.

The group said these patent filings follow on from a total of five successful independent human studies in which OptiBiotix's products and comparator samples were tested by an expert panel of 11 panellists who rated 11 products attributes - e.g. sweetness, aftertaste, off- flavour, bitterness etc - compared to sucrose.

The obesity and cholesterol management company said that the global sweetener market, currently dominated by sugar, is forecast to reach US$112bln by 2020. Therefore, the firm believes filing these additional patents will help protect its inventions and fully exploits the commercial opportunities being explored with industry partners.

Stephen O’Hara, OptiBiotix's CEO said: “With growing concerns over traditional sugars and artificial sweeteners, SweetBiotix has the potential to address a global consumer and industry need, addressing international concerns over the impact of sugar an obesity, with the prospect of replacing ‘unhealthy’ sugars in existing products with non-digestible, low calorie, healthy, SweetBiotix.”

]]>
Thu, 05 Apr 2018 07:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/194307/optibiotix-health-announces-three-new-patent-filings-in-the-sweetener-market-194307.html